

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Modified PTO Form 1449	Atty. Docket No. 11245/46604	Serial No. 07/840,146 Not Yet Assigned
	Applicant Harlan W. WAKSAL	
	Filing Date April 24, 2001	Group 1642

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
Alt	4,863,902	9/5/89	Amagase et al			
Alt	4,943,533	7/24/98	Mendelsohn et al.			
Alt	5,846,565	12/8/98	Brem et al.			
Alt	5,468,754	11/21/95	Hausheer et al.			
Alt	5,559,235	9/24/96	Luzzio et al.			
Alt	5,604,233	2/18/97	Hausheer et al.			
Alt	5,880,133	3/9/99	Hausheer et al.			


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
Alt	EP 0 359 282 B1	5/95	EPO				

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
Alt		Han et al., "Preferential Inhibition of Glioblastoma Cells With Wild-Type Epidermal Growth Factor Receptors by a Novel Tyrosine Kinase Inhibitor Ethyl-2,5-Dihydroxycinnamate"; Oncology Research, Vol. 9, pages 581-587 (1997)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449	ATTY. DOCKET NO. 11245/46604	SERIAL NO. 09/840,146
	APPLICANT H. WAKSAL	EXAMINER J. Hunt <i>HOLLERMAN</i>
	FILING DATE April 24, 2001	GROUP 1642



U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	REMARKS DATE*

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

RECEIVED
FEB 26 2002
TECH CENTER 1600/2900

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
<i>ALH</i>	U.S. Patent Application of Dr. Mark Rubin, filed March 2001

EXAMINER <i>Anne C. Holleran</i>	DATE CONSIDERED <i>12/16/02</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
ArH		Baselga et al., "The epidermal growth factor receptor as a target for therapy in breast carcinoma", Breast Cancer Research and Treatment, Volume 29, pages 127-138 (1994)
ArH		Osband and Ross, "Problems in the investigational study and clinical use of cancer immunotherapy", Immunotherapy, pages 193-195
ArH		"Antitumor Effects of Doxorubicin in Combination with Anti-epidermal Growth Factor Receptor Monoclonal Antibodies", J. Baselga, L. Norton, H. Masui, A. Pandiella, K. Coplan, W.H. Miller, Jr., J. Mendelsohn; Journal of the National Cancer Institute, Vol. 35, No. 16, 1327-1333 (1993)
ArH		"Antitumor Effect of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies plus cis-Diamminedichloroplatinum on Well Established A431 Cell Xenografts", Z. Fan, J. Baselga, H. Masui, J. Mendelsohn; Cancer Research, Vol. 53, 4637-4641(1993)
ArH		"Anti-tumor and Cell Cycle Responses on KB Cells Treatment with a Chimeric Anti-EGFR Monoclonal Antibody Incombination with Cisplatin", M. Brewett, P. Rockwell, C. Rose, N.I. Goldstein, Immunology Department, Imclone Systems, Inc., International Journal of Oncology 21: 224 (1996) 9(2):
ArH		Abstract entitled "Immunochemotherapy of Human Transitional Cell Carcinoma (TCC) with Anti-EGF-R Monoclonal Antibody (Mab) C225 and the Anti-cancer Drugs, Taxol and Cisplatinum", AACR Annual Meeting, March 28-April 1998, New Orleans, LA 39: 7964 tum, 4.B.
ArH		"Inhibition of Human Tumor Growth in Nude Mice by a Conjugate of Doxorubicin with Monoclonal Antibodies to Epidermal Growth Factor Receptor", E. Aboud-Pirak, E. Hurwitz, F. Bellot, J. Schlessinger, M. Sela, Proc. Natl. Acad. Ser. U.S.A., Vol. 86, pp. 3778-3781 (1989)
ArH		"Role of Protein Tyrosine Kinase Receptors in Cancer: Possibilities for Therapeutic Intervention", P. Rockwell, N.I. Goldstein; Molecular and Cellular Dir. 3 (4) 315-335 (1995) Molecular Differentiation
Examiner	<div> <div> Anne L. Holleran </div> <div> Date Considered 12/16/02 </div> </div>	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

*copy of reference is not enclosed because reference is cited in search report